Use of OCT to Localize Macrophages

Slides:



Advertisements
Similar presentations
When Should a Clinical Trial Design with Pre-Stratification be Used? Group 1.
Advertisements

Tobias Reichlin, W. Hochholzer, C. Stelzig, K. Laule, M. Potocki, K
Implications from PROSPECT and Future Directions Gregg W. Stone, MD Columbia University Medical Center The Cardiovascular Research Foundation Providing.
IVUS-VH & Vulnerable Plaque Jang-Ho Bae, MD., PhD. Heart Center Konyang University Hospital Daejeon City, S. Korea Jang-Ho Bae, MD., PhD. Heart Center.
Vulnerable Plaque 분당서울대학교병원 심장센터 연 태 진. Causes / mediators of atherothrombosis Endothelial dysfunction Fatty streak Fibrous plaque Unstable Fibrous plaque.
Stents Are Not Enough: Statins Keith Channon Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford.
Acute Coronary Syndromes and The Inflammation Theory: Fact or Fiction Rabih R. Azar, MD, MSc, FACC Associate Professor of Medicine Saint-Joseph University.
Rate of Obstructive Coronary Disease in Elective Diagnostic Cath Manesh R. Patel, MD Assistant Professor of Medicine Director Cath Lab Research – Duke.
Departments of Medicine and Biostatistics
ISCHAEMIC HEART DISEASE Acute Coronary Syndromes JD Marx Department of Cardiology University of the Free State.
The BHF FAMOUS NSTEMI Trial For the FAMOUS NSTEMI Investigators ESC Hotline for Myocardial Infarction, 1 Sep 2014 J. Layland, K.G. Oldroyd, N. Curzen,
The BHF FAMOUS NSTEMI Trial For the FAMOUS NSTEMI Investigators ESC Hotline for Myocardial Infarction, 1 Sep 2014 J. Layland, K.G. Oldroyd, N. Curzen,
Extracellular cholesterol and cholesterol-filled macrophages (foam cells) accumulate in subendothelial space. Subsequent structural modifications of LDL.
Navigating the Coronary Circulation: Angiography vs IVUS Pearls and Pitfalls Philippe L. L’Allier, MD Montreal Heart Institute Tuesday, March 27, 2007.
Calcium score as a predictor of coronary artery disease severity in patients with acute coronary syndromes Coordinator Author Prof.Dr.Benedek Theodora.
Baseline Characteristics of the Patient Population (n=525) Colin Berry, et al. Circulation 2007;115:
New techniques for the “invasive diagnosis” of the vulnerable plaque Antwerp, 17 March 2006.
R4 하 상 진. Introduction Circulation May 1;115(17):
The REVA Tyrosine-Derived Polycarbonate Bioresorbable Scaffold: Long-term Outcomes Using Multimodality Imaging Greg L. Kaluza, MD, PhD, FACC Director of.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Dual Lipid-Lowering Strategy With Ezetimibe.
Disclosure Statement of Financial Interest
Disclosure Statement of Financial Interest
It’s Both the Vulnerable Patient and the Vulnerable Plaque
The Power of New Biomarkers to Detect Early Ischemia
Atherosclerosis and HDL Therapy New Virtual Histology Findings
Journal of Cardiovascular Computed Tomography
Acute coronary syndrome secondary to in-stent plaque rupture occurred at 9 years after deployment of bare metal stent  Hiroyuki Kunii, MD, Tetsuro Yokokawa,
Ischemic Heart Disease
Can NIRS Detect Vulnerable Plaque? The Rotterdam Experience
Stephen J Nicholls MBBS PhD FRACP FACC
Plaque Stabilization by Statin: From EASY-FIT to ESCORT Trial
OCT and Stent Thrombosis
CTA Characterization of Vulnerable Plaque Minneapolis Heart Institute
The Role of Inflammation and Immune Responses
Cardiovascular Research Technologies
Near-Infrared Spectroscopy: Lipid-Rich Plaque Study Update
Novel Biomarkers in Coronary Artery Disease
Should we Use OCT in STEMI Patients?
Clinical need for determination of vulnerable plaques
Near Infrared Spectroscopy: Case Studies and Clinical Relevance
David J. Cohen, M.D., M.Sc. Director of Cardiovascular Research
Harmonized Assessment by Randomized Multicenter Study of OrbusNEich’s COMBO StEnt Japan-USA HARMONEE: Primary Report of A Randomized Trial of a Bioabsorbable.
Greg L. Kaluza, MD, PhD, FACC Cardiovascular Research Foundation
Surrogate Endpoints Laura Mauri, MD, MSc Brigham and Women’s Hospital
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology PET Measurements of Myocardial Blood flow Post Myocardial.
Plaque rupture, thrombosis, and healing. A
Advanced carotid plaque characterization: Assessment of vulnerability
OCT-Guided PCI What needs to be done to establish criteria?
Left Anterior Descending Artery Myocardial Bridging
Progenitor Endothelial Cell Capturing with a Drug Eluting Stent
William Wijns MD PhD Thomas Cuisset MD
Early strut coverage in patients receiving new-generation drug-eluting stents and its implications for dual antiplatelet therapy: a randomized clinical.
William Insull, MD  The American Journal of Medicine 
Markers of instability in high-risk carotid plaques are reduced by statins  Hagen Kunte, MD, Nicola Amberger, MD, Markus Alexander Busch, MD, MPH, Ralph-Ingo.
Increased vascularization of shoulder regions of carotid atherosclerotic plaques from patients with diabetes  Fredrik J. Olson, PhD, Sofia Strömberg,
International Journal of Cardiology
Volume 383, Issue 9918, Pages (February 2014)
Section 4: Plaque dynamics and stenosis
N. Rama Kumari, I. Bhaskara Raju, M. Aruna Devi, J. Rama Krishna, K
Markers of instability in high-risk carotid plaques are reduced by statins  Hagen Kunte, MD, Nicola Amberger, MD, Markus Alexander Busch, MD, MPH, Ralph-Ingo.
Degree of carotid plaque calcification in relation to symptomatic outcome and plaque inflammation  Wael E Shaalan, MD, Hongwei Cheng, MD, PhD, Bruce Gewertz,
Histopathological comparison between endofibrosis of the high-performance cyclist and atherosclerosis in the external iliac artery  Aryan Vink, MD, PhD,
HILLSBOROUGH COUNTY SHERIFF’S DEPARTMENT
Nat. Rev. Cardiol. doi: /nrcardio
Charis Costopoulos et al. JIMG 2017;10:
Critical carotid stenoses: Morphologic and chemical similarity between symptomatic and asymptomatic plaques  Hisham S. Bassiouny, MD, Harry Davis, PhD,
How to reduce the risk of plaque rupture
Fig. 10. COL15A1 is pervasive within advanced human atherosclerotic plaques and localized to the fibrous cap and intraplaque microvessels. A representative.
FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.
Presentation transcript:

Use of OCT to Localize Macrophages Ik-Kyung Jang, MD, PhD Professor of Medicine Harvard Medical School

Disclosure Research grant: LLI/St Disclosure Research grant: LLI/St. Jude medical, Medtronic, Abbott Vascular, JNJ Consultant: LLI/St. Jude medical

Macrophages by OCT Stable Angina Post-MI T LP LP Lumen

Ex Vivo Macrophage Study Low Mf High Mf 250 µm OCT CD68

Linear NSD vs. CD68 CD68 % area > 10 % - NSD cutoff 6.2% SENS 100% (70-100%) SPEC 100% (60 -100%) Tearney. Circulation, 2003

Macrophage Analysis (119 plaques) Cap segmentation- Entire fibrous cap Rupture Surface: < 50 µm from lumen Subsurface: > 50 µm from lumen NSD computation- Definition: Macrophage Density ~ Mean NSD within Segmented Region 0% 10%

Tissue Property Analysis

Tissue Property Analysis

Evaluation of Macrophage in Patients Macrophage density ~ clinical syndrome Rupture vs. non-rupture site density Surface vs. subsurface density

Macrophage Density Clinical Presentations * *P < 0.001

Macrophage Density Culprit vs. Remote Sites

Macrophage Density Rupture Sites

Macrophage Density Surface versus Subsurface Culprit Remote Surface AUC = 0.79 Subsurface AUC = 0.69 P = 0.035 Surface AUC = 0.73 Subsurface AUC = 0.72 P = 0.80 Surface cap macrophage density is more predictive of clinical syndrome than subsurface macrophage density at culprit, but not remote sites

Aim of the study Evaluate the relationships between local plaque fibrous cap macrophage density, the peripheral WBC count, and the plaque characteristics

Correlation of WBC count with Macrophage Density and Fibrous Cap Thickness 16.0 14.0 12.0 10.0 8.0 6.0 4.0 WBC count 2.0 0.0 Macrophage Density (%) 5.5 5.0 4.5 3.5 3.0 2.5 Fibrous Cap Thickness (Ln) r = 0.483, p < 0.001 r = - 0.423, p < 0.013

Association Between Macrophage Density and Fibrous Cap Thickness 10.0 8.0 6.0 4.0 2.0 5.5 5.0 4.5 3.5 3.0 2.5 Ln of Fibrous Cap Thickness

Macrophage Density Non TCFA vs TCFA 9.0 A p < 0.001 8.0 7.0 6.0 5.0 4.0 3.0 5.0 (1.9) 7.4 (1.8) Non TCFA TCFA Values are median (interquartile range)

Aim of the study remodeling assessed by IVUS and underlying Evaluate the association between coronary artery remodeling assessed by IVUS and underlying macrophage density identified by OCT

Association Between Remodeling and Underlying Plaque Macrophage Density 7.0 6.9 6.0 5.8 Mean Macrophage Density (NSD %) 5.0 4.0 3.9 3.0 Positive Absent Negative

Summary Macrophage can be detected and localized in vivo. Increased Macrophage density in ACS. Correlation between macrophage density and plaque characteristics (TCFA) and systemic inflammation (WBC). Correlation between macrophage density and positive remodeling.

Limitations The difference in macrophage density is marginal.

Limitations The difference in macrophage density is marginal. Enzymatic activity of macrophage is not known. Measuring NSD, not macrophage. 4. Prognostic utility is unknown.